

### Malaria

- *P. falciparum* is the commonest cause of malaria in Kenya (98.2%); *P. malariae* and *P. ovale* is 1.8%, often occurring as mixed infections. (Surveys have not identified the presence of *P. vivax* in Kenya)
- Endemic areas are around Lake Victoria in Western Kenya and coastal regions; other areas have seasonal transmission depending on temperature and rainfall; central highlands area (Nairobi and Kijabe) is a low-risk malaria area

#### Severe malaria

(one or more of the following parameters, occurring in the absence of an identified alternative cause and in the presence of *P. falciparum* asexual parasitaemia)

##### Clinical parameters


- Impaired consciousness
- Prostration
- Convulsions
- Pulmonary oedema
- Significant bleeding
- Shock

##### Lab/clinical parameters

- Acidosis (respiratory distress)
- Hypoglycaemia
- Severe anaemia
- Renal impairment
- Jaundice
- Hyperparasitaemia (>10%)

- Malaria is classified as **either uncomplicated or severe**, based on clinical presentation (see table)
- Artemether-Lumefantrine (AL) is first-line treatment for all types of uncomplicated malaria. Once commenced, the 3 days must always be completed.
- New advice: **first line treatment for pregnant women** with uncomplicated *P. falciparum* malaria in the first trimester is now AL (and no longer quinine)

### Diagnosis and treatment of malaria



| Dosing schedule for Artemether Lumefantrine<br>(6 doses over 3 days at 0h, 8h, 24h, 36h, 48h, 60h) |                    |   |
|--|--------------------|---|
| Weight   | Age                | Dose of AL<br>(ALL doses must be taken) |
| 5 - 14 Kg  | 5 months – 3 years | 20mg / 120mg                            |
| 15 - 24 Kg   | 3 – 7 years        | 40mg / 240mg                            |
| 25 - 34 Kg   | 8 – 11 years       | 60mg / 360mg                            |
| ≥ 35 Kg  | ≥ 12 years         | 80mg / 480mg                            |

### Immediate clinical management of severe manifestations and complications of *P. falciparum* malaria (WHO)

| Manifestation or complication  | Immediate management<br>(It is assumed that appropriate antimalarial treatment will have been started in all cases)  |
|--|--|
| <b>Coma (cerebral malaria)</b>   | Maintain airway, place patient on his or her side, exclude other treatable causes of coma (e.g. hypoglycaemia, bacterial meningitis); avoid harmful ancillary treatments (corticosteroids NOT indicated), intubate if necessary.   |
| <b>Hyperpyrexia</b>  | Administer tepid sponging, fanning, a cooling blanket and paracetamol.   |
| <b>Convulsions</b>   | Maintain airways; treat promptly with intravenous or rectal diazepam, lorazepam, midazolam or intramuscular paraldehyde. Check blood glucose.  |
| <b>Hypoglycaemia</b>   | Check blood glucose, correct hypoglycaemia and maintain with glucose- containing infusion. Although hypoglycaemia is defined as glucose < 2.2 mmol/L, the threshold for intervention is < 3 mmol/L for children < 5 years and <2.2 mmol/L for older children and adults.   |
| <b>Severe anaemia</b>  | Transfuse with screened fresh whole blood.<br>In high-transmission settings, blood transfusion is generally recommended for children with a haemoglobin level of <5 g/100 mL (haematocrit < 15%). In low-transmission settings, a threshold of 20% (haemoglobin, 7 g/100 mL) is recommended.<br>(Many anecdotal reports and several series have claimed the benefit of exchange blood transfusion in severe malaria, but there have been no comparative trials, and there is no consensus on whether it reduces mortality or how it might work.)               |
| <b>Acute pulmonary oedema</b>  | (Prevent by avoiding excess hydration)<br>Prop patient up at an angle of 45 degrees, give oxygen, give a diuretic, stop IV fluids, intubate and add positive end-expiratory pressure or CPAP in life-threatening hypoxaemia.   |
| <b>Acute kidney injury</b>   | Exclude pre-renal causes, check fluid balance and urinary sodium; if in established renal failure, add haemofiltration or haemodialysis.   |
| <b>Spontaneous bleeding and coagulopathy</b>   | Transfuse with screened fresh whole blood (cryoprecipitate, fresh frozen plasma and platelets, if available); give vitamin K injection.  |
| <b>Metabolic acidosis</b>  | Often associated with severe anaemia in children and needs to be treated by blood transfusion (10mg/kg whole blood). Also exclude or treat hypoglycaemia, hypovolaemia and septicaemia. If severe, add haemofiltration or haemodialysis.   |
| <b>Shock</b>   | Suspect septicaemia, take blood for cultures; give parenteral broad- spectrum antimicrobials, correct haemodynamic disturbances.   |
| <b>Fluid therapy</b>   | Fluid requirements should be assessed individually. Adults with severe malaria are very vulnerable to fluid overload, while children are more likely to be dehydrated. Rapid bolus infusion of colloid or crystalloids is contraindicated. Need for blood in metabolic acidosis (respiratory distress) with anaemia in children. In adults there is a thin-line between overhydrating, producing pulmonary oedema, and underhydrating. Careful, frequent evaluation of JVP, peripheral perfusion, venous filling, skin turgor and urine output should be made. |
| <b>Antibiotics</b>   | The threshold for administering antibiotic treatment should be low in severe malaria. Septicaemia and severe malaria are associated, and there is substantial diagnostic overlap, particularly in children in areas of moderate and high transmission. Thus broad-spectrum antibiotic treatment <i>should be given</i> with antimalarial drugs to all children with suspected severe malaria in areas of moderate and high transmission until a bacterial infection is excluded, so consider in our context. Watch for secondary pneumonia.                    |
| <b>Note: use of corticosteroids increases the risk for gastrointestinal bleeding and seizures and has been associated with prolonged coma resolution times when compared with placebo.</b> |  |

### Preventing relapse in *P. ovale* (and *P vivax*) malaria

After treatment of *P ovale* (and *P vivax*) infection with AL, patients should be treated to prevent relapse:

- **Non-pregnant and non-lactating patients:** check G6PD status, if no deficiency give primaquine (0.5mg base/kg daily for 14d)
- **Pregnant women:** Chloroquine 300mg/week for the duration of the pregnancy, then test baby and mother for G6PD deficiency
- **Breast-feeding women:** check G6PD status of infant and mother and give primaquine if no deficiency
- **Mild-moderate G6PD deficiency:** can give 0.75mg primaquine once weekly for 8 weeks
- **Severe G6PD deficiency:** primaquine contraindicated

### Chemoprophylaxis against falciparum malaria:

- For those from a non-endemic area who are travelling into an endemic area.
- Also advise early medical care if they develop fever within 3 months of travel to an endemic area, and **to use barrier methods**. Travellers may want to take RDTs with them and a course of AL, especially if going to a remote area.
- Chemoprophylaxis is also used in endemic areas of Kenya for those with sickle cell disease and those with tropical splenomegaly syndrome (TSS) – currently proguanil
- Intermittent preventive treatment of malaria in pregnancy (IPTp) is recommended in areas of high malaria transmission in Kenya

| Drug                                   | Length of treatment  | Dosage  | Use in pregnancy  | Notes   |
|--|--|---|---|---|
| <b>Atovaquone/proguanil (Malarone)</b> | Start 1-2d before entering endemic area; continue for 7d after leaving           | 250/100mg tablets<br>Adults (weight $\geq 40$ kg): 1 tablet per day<br>Weight 30-39kg: $\frac{3}{4}$ tablet per day<br>Weight 20-29kg: $\frac{1}{2}$ tablet per day<br><br>62.5/25mg tablets:<br>Weight 10-19kg: 1 tablet per day<br>Weight 8-9kg: $\frac{3}{4}$ tablet per day<br>Weight 5-7kg: $\frac{1}{2}$ tablet per day | Small studies show no problems, but larger studies are needed. Risk of malaria needs to be balanced with possible risk of medication<br><a href="https://www.medicinesinpregnancy.org/Medicine-pregnancy/Malarone/">https://www.medicinesinpregnancy.org/Medicine-pregnancy/Malarone/</a> | Side effects: abdo pain, nausea, vomiting, diarrhoea, headache, anorexia, coughing, depression, Contraindicated: renal failure  |
| <b>Doxycycline</b>                     | Start 1-2d before entering endemic area; continue for 4 weeks after leaving      | Adults (children $\geq 50$ kg): 100mg per day<br><br>If tablets are available, smaller doses can be given to children (approx. 2mg/kg, max 100mg)<br>Age 11-13 (36-50kg): 75mg/d<br>Age 8-10 (25-35kg): 50mg/d<br>Age <8: contraindicated   | No  | Side effects: GI irritation, increased vulnerability to sunburn, discolouration of growing teeth<br>Contraindicated: liver disease  |
| <b>Mefloquine</b>                      | Start 2-3 weeks before entering endemic area; continue for 4 weeks after leaving | Adults (weight $\geq 45$ kg): 250mg once weekly<br>Weight 25-44kg: 187.5mg once weekly<br>Weight 16-24kg: 125mg once weekly<br>Weight 5-15kg: 62.5mg once weekly<br><3 months (<5kg): not recommended   | Yes   | Avoid if history of seizures or psychiatric disorders (including depression). Do not administer with quinine<br>Side effects: sleep disturbance, anxiety, depression, diarrhoea, dizziness, abdo pain, headache, nausea |

### References

WHO guidelines for malaria, March 2023

Basic Paediatric Protocols 2016 4<sup>th</sup> Edition

National guidelines for the diagnosis, treatment and prevention of malaria in Kenya, 5<sup>th</sup> edition, MOH 2016

UpToDate accessed 12/6/23